Neose Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation therapeutic proteins that are competitive with best-in-class protein drugs currently on the market. The lead candidates in our pipeline, GlycoPEG-GCSF for chemotherapy-induced neutropenia, and GlycoPEGylated Factors VIIa, VIII and IX for hemphilia, target markets with 2006 aggregate sales of approximately $8 billion.
Print
right half of page content